Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab + durvalumab with concurrent TACE in unresectable hepatocellular carcinoma
KCT0010173Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2025
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tremelimumab and durvalumab in hepatocellular carcinoma (HCC), sponsored by AstraZeneca. Primary endpoints: Progression-free survival, Overall survival and 2 more. Started Apr 2025; status: recruiting.
02
Drugs
tremelimumabdurvalumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on KCT0010173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010173.